Newsflash:
- Many Drug Labels Missing Dose, Safety Info for Kids
- Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer
- J&J Opens Doxil Rationing Program to New Patients
- FDA Issues Safety Label Changes for Fingolimod
- FDA Backs Pill to Block HIV Infection
- FDA Advisers Recommend Approving Arena Weight-Loss Drug
Glaxo to File Advair Replacement Relovair in Mid-2012
Dow Jones Newswires (01/09/12) Stovall, Sten
GlaxoSmithKline and U.S.-based partner Theravance said they plan to submit their key new lung drug Relovair for regulatory approval in mid-2012 following encouraging late-stage trial results. The convenience of Relovair's once-a-day dosing is expected to give the product a valuable advantage in the huge market for lung medicines. The product will also be submitted as a new treatment for asthma in Europe at the same time, while in the U.S., Glaxo and Theravance will continue discussions with the Food & Drug Administration on its use in asthma.
Abstract News © Copyright 2011
INFORMATION, INC.
Sponsor Highlights
Our Sponsors:
Sitemap
© Pharmacist e-Link
